Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction.
Standard
Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction. / Mahner, Sven; Wölber, Linn; Jung, Sabine; Zu Eulenburg, Christine Gräfin; Henningsen, Maike; Schwarz, Joerg; Sehouli, Jalid; Jänicke, Fritz.
In: ANTICANCER RES, Vol. 29, No. 7, 7, 2009, p. 2817-2821.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction.
AU - Mahner, Sven
AU - Wölber, Linn
AU - Jung, Sabine
AU - Zu Eulenburg, Christine Gräfin
AU - Henningsen, Maike
AU - Schwarz, Joerg
AU - Sehouli, Jalid
AU - Jänicke, Fritz
PY - 2009
Y1 - 2009
N2 - BACKGROUND: Despite radical surgical and chemotherapeutic treatment of ovarian cancer, the majority of patients develop recurrence and die due to progressive disease. Routine measurement of the tumor marker CA-125 is often used in the follow-up management. However, the role of preoperative CA-125 as a prognostic factor before secondary cytoreduction of relapsed ovarian cancer has not been determined. PATIENTS AND METHODS: CA-125 serum concentration and relevant clinico-pathological variables were analyzed regarding their potential prognostic impact in patients selected for secondary cytoreduction of recurrent epithelial ovarian cancer. RESULTS: In total, 48 patients underwent secondary cytoreduction at the University Medical Center Hamburg-Eppendorf between 1996 and 2004 and 36 patients were evaluable for serum CA-125 concentration. Median age was 60 years (range 30-78 years) and median relapse-free survival before secondary cytoreduction was 18 months. The median time to progression after secondary surgery was 22 months (range 1-100 months), and median overall survival was 26 months (range 1-100 months). Serum CA-125 at the time of secondary cytoreduction was elevated (>35 kU/L) in 30 of 36 patients (81%) with a median of 212 kU/L (range 6-3866 kU/L). Multivariate analysis did not reveal a prognostic significance for preoperative CA-125. The only independent prognostic factors of improved survival were progression-free interval before secondary cytoreduction (p=0.047) and minimal residual disease after secondary cytoreduction (p=0.024). CONCLUSION: Although most patients had elevated serum CA-125 at the time of secondary cytoreductive surgery, CA-125 had no prognostic relevance.
AB - BACKGROUND: Despite radical surgical and chemotherapeutic treatment of ovarian cancer, the majority of patients develop recurrence and die due to progressive disease. Routine measurement of the tumor marker CA-125 is often used in the follow-up management. However, the role of preoperative CA-125 as a prognostic factor before secondary cytoreduction of relapsed ovarian cancer has not been determined. PATIENTS AND METHODS: CA-125 serum concentration and relevant clinico-pathological variables were analyzed regarding their potential prognostic impact in patients selected for secondary cytoreduction of recurrent epithelial ovarian cancer. RESULTS: In total, 48 patients underwent secondary cytoreduction at the University Medical Center Hamburg-Eppendorf between 1996 and 2004 and 36 patients were evaluable for serum CA-125 concentration. Median age was 60 years (range 30-78 years) and median relapse-free survival before secondary cytoreduction was 18 months. The median time to progression after secondary surgery was 22 months (range 1-100 months), and median overall survival was 26 months (range 1-100 months). Serum CA-125 at the time of secondary cytoreduction was elevated (>35 kU/L) in 30 of 36 patients (81%) with a median of 212 kU/L (range 6-3866 kU/L). Multivariate analysis did not reveal a prognostic significance for preoperative CA-125. The only independent prognostic factors of improved survival were progression-free interval before secondary cytoreduction (p=0.047) and minimal residual disease after secondary cytoreduction (p=0.024). CONCLUSION: Although most patients had elevated serum CA-125 at the time of secondary cytoreductive surgery, CA-125 had no prognostic relevance.
M3 - SCORING: Zeitschriftenaufsatz
VL - 29
SP - 2817
EP - 2821
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 7
M1 - 7
ER -